10 Best Small-Cap Stocks Ready To Explode

6. Dynavax Technologies Corporation (NASDAQ:DVAX)

Analyst Upside Potential: 104.75%

Dynavax Technologies Corporation (NASDAQ:DVAX) is a commercial-stage biopharmaceutical company focused on developing and commercializing vaccines. Its primary product is HEPLISAV-B, a hepatitis B vaccine designed for adults aged 18 and older, which requires only two doses for effective immunization against all known subtypes of the hepatitis B virus. Additionally, the company also produces CpG 1018, an adjuvant that enhances the immune response and is used in HEPLISAV-B as well as in various COVID-19 vaccines. It is also working on a pipeline of new vaccine candidates targeting diseases such as shingles, tetanus, diphtheria, and plague.

Its HEPLISAV-B vaccine is a market differentiator. According to the company’s third-quarter report for fiscal 2024, the vaccine improved its United States market share from 41% last year to 44% during the most recent quarter. Due to the increase in market share of the vaccine, the net product revenue of HEPLISAV-B grew 27% year-over-year in Q3 2024 to reach $79.3M. Management is aiming to grow the market share of HEPLISAV-B to at least 60% by 2030.

The company has been growing its top and bottom line at a steady pace. During the third quarter, its total revenue improved 16% year-over-year to reach $80.6 million. Whereas, its net income grew by 23% year-over-year to reach $17.6 million. Management believes that Dynavax Technologies Corporation (NASDAQ:DVAX) is on track to achieve net product revenue of $265 million to $270 million for HEPLISAV-B and that too at around 80% gross margins during 2024. Moreover, they also expect the net income to remain positive during the rest of the year.

In addition, analysts’ 12-month median price target is pointing towards a 104.75% upside from the current levels making it one of the best small-cap stocks ready to explode.